Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Optogenetic, electrophysiological and live-cell imaging investigation of LRRK2 in synaptic transmission.
EF 2015-16
Résumé
Parkinson's disease (PD) is the second most common neurodegenerative disease. The cardinal symptoms of PD include severe stiffness, hand tremor and slow, uncoordinated movement as well as non-motor symptoms such as depression and dementia. These symptoms have been linked to the degeneration of neurons producing a specific neurotransmitter, dopamine. The economic burden of the disease is high ($20 billion per in the US), and is expected to rapidly increase with increasingly aging global population.Effective treatments currently exist for the motor symptoms however; they do not halt progression and are simply temporarily alleviating the symptoms. This is because most research has focused on replicating late stage PD pathology rather than targeting the cause of the degeneration. Recently several mutations were linked to familial PD, and have been developed into mouse models. The most common mutations lie in the leucine rich repeat kinase 2 gene (LRRK2). I will use these mouse models to investigate the mechanism underlying early changes that lead to the development of the disease. The function of LRRK2 has been elusive but hints are now appearing that it is tied to trafficking and recycling of small pockets of neurotransmitters, synaptic vesicles. I aim to elucidate how the disease causing mutation alters synaptic vesicle dynamics using techniques that allow me to visualize the movement and location of these vesicles in real time. Ultimately understanding the specific ways this mutation disrupts the function of the protein I will illuminate new neuroprotective targets for treatment that halts or reverses the progression of the disease.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
350048
Name
Tatarnikov Igor
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Optogenetic, electrophysiological and live-cell imaging investigation of LRRK2 in synaptic transmission.
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Early Pathophysiological Alterations; Electrophysiology; Optogenetics; Parkinson'S Disease; Synaptic Release
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease. The cardinal symptoms of PD include severe stiffness, hand tremor and slow, uncoordinated movement as well as non-motor symptoms such as depression and dementia. These symptoms have been linked to the degeneration of neurons producing a specific neurotransmitter, dopamine. The economic burden of the disease is high ($20 billion per in the US), and is expected to rapidly increase with increasingly aging global population.Effective treatments currently exist for the motor symptoms however; they do not halt progression and are simply temporarily alleviating the symptoms. This is because most research has focused on replicating late stage PD pathology rather than targeting the cause of the degeneration. Recently several mutations were linked to familial PD, and have been developed into mouse models. The most common mutations lie in the leucine rich repeat kinase 2 gene (LRRK2). I will use these mouse models to investigate the mechanism underlying early changes that lead to the development of the disease. The function of LRRK2 has been elusive but hints are now appearing that it is tied to trafficking and recycling of small pockets of neurotransmitters, synaptic vesicles. I aim to elucidate how the disease causing mutation alters synaptic vesicle dynamics using techniques that allow me to visualize the movement and location of these vesicles in real time. Ultimately understanding the specific ways this mutation disrupts the function of the protein I will illuminate new neuroprotective targets for treatment that halts or reverses the progression of the disease.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tatarnikov, Igor
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~